Susquehanna International Group
AKBA icon

Susquehanna International Group’s Akebia Therapeutics AKBA Stock Holding History

Susquehanna International Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1M Buy
722,119
+74,406
+11% +$102K ﹤0.01% 7874
2025
Q4 		$1.04M Buy
647,713
+155,379
+32% +$325K ﹤0.01% 7092
2025
Q3 		$1.34M Sell
492,334
-299,018
-38% -$995K ﹤0.01% 6635
2025
Q2 		$2.88M Buy
791,352
+104,073
+15% +$286K ﹤0.01% 5038
2025
Q1 		$1.32M Buy
687,279
+101,182
+17% +$207K ﹤0.01% 6548
2024
Q4 		$1.11M Buy
586,097
+421,527
+256% +$732K ﹤0.01% 6681
2024
Q3 		$217K Sell
164,570
-84,243
-34% -$112K ﹤0.01% 10303
2024
Q2 		$254K Sell
248,813
-1,513,601
-86% -$1.87M ﹤0.01% 9822
2024
Q1 		$3.23M Sell
1,762,414
-396,950
-18% -$635K ﹤0.01% 4376
2023
Q4 		$2.68M Buy
2,159,364
+1,408,923
+188% +$1.44M ﹤0.01% 4778
2023
Q3 		$856K Buy
750,441
+425,309
+131% +$546K ﹤0.01% 6991
2023
Q2 		$297K Sell
325,132
-46,382
-12% -$44.8K ﹤0.01% 9449
2023
Q1 		$208K Sell
371,514
-155,644
-30% -$119K ﹤0.01% 10512
2022
Q4 		$304K Buy
527,158
+64,558
+14% +$20.2K ﹤0.01% 9062
2022
Q3 		$146K Sell
462,600
-66,850
-13% -$26.2K ﹤0.01% 11274
2022
Q2 		$187K Buy
529,450
+44,166
+9% +$18.5K ﹤0.01% 10732
2022
Q1 		$348K Sell
485,284
-370,291
-43% -$792K ﹤0.01% 9894
2021
Q4 		$1.93M Buy
855,575
+67,362
+9% +$184K ﹤0.01% 5584
2021
Q3 		$2.27M Sell
788,213
-156,615
-17% -$447K ﹤0.01% 5554
2021
Q2 		$3.58M Sell
944,828
-240,227
-20% -$809K ﹤0.01% 4675
2021
Q1 		$4.01M Buy
1,185,055
+603,124
+104% +$2.17M ﹤0.01% 4350
2020
Q4 		$1.63M Sell
581,931
-122,539
-17% -$358K ﹤0.01% 5546
2020
Q3 		$1.77M Buy
704,470
+659,158
+1,455% +$5.78M ﹤0.01% 4864
2020
Q2 		$615K Sell
45,312
-116,799
-72% -$1.21M ﹤0.01% 6926
2020
Q1 		$1.23M Sell
162,111
-36,284
-18% -$282K ﹤0.01% 4910
2019
Q4 		$1.25M Buy
198,395
+46,880
+31% +$223K ﹤0.01% 5094
2019
Q3 		$594K Sell
151,515
-36,402
-19% -$156K ﹤0.01% 6902
2019
Q2 		$909K Buy
+187,917
New +$1.07M ﹤0.01% 5890
2019
Q1 		– Sell
-221,526
Closed -$1.52M – 8736
2018
Q4 		$1.23M Buy
221,526
+207,297
+1,457% +$1.62M ﹤0.01% 4309
2018
Q3 		$126K Sell
14,229
-59,483
-81% -$532K ﹤0.01% 8506
2018
Q2 		$736K Buy
+73,712
New +$738K ﹤0.01% 6030
2017
Q3 		– Sell
-72,701
Closed -$1.12M – 8744
2017
Q2 		$1.04M Buy
+72,701
New +$922K ﹤0.01% 5166
2017
Q1 		– Sell
-54,721
Closed -$534K – 8849
2016
Q4 		$570K Buy
54,721
+44,520
+436% +$383K ﹤0.01% 6709
2016
Q3 		$92K Sell
10,201
-30,754
-75% -$261K ﹤0.01% 7970
2016
Q2 		$306K Buy
40,955
+10,803
+36% +$94.3K ﹤0.01% 6921
2016
Q1 		$272K Sell
30,152
-16,852
-36% -$137K ﹤0.01% 7421
2015
Q4 		$607K Buy
+47,004
New +$480K ﹤0.01% 6393
2015
Q2 		– Sell
-11,659
Closed -$99.5K – 10060
2015
Q1 		$130K Sell
11,659
-2,025
-15% -$21.6K ﹤0.01% 8869
2014
Q4 		$159K Buy
+13,684
New +$196K ﹤0.01% 8975
2014
Q3 		– Sell
-14,777
Closed -$339K – 9372
2014
Q2 		$411K Buy
+14,777
New +$356K ﹤0.01% 7839

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Susquehanna International Group's AKBA Position: Q1 2026 in Review

Susquehanna International Group increased its Akebia Therapeutics (AKBA) stake by 11% in Q1 2026, buying an estimated $102K and bringing the position to 722,119 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #7874.

Susquehanna International Group first reported a position in AKBA in Q2 2014 and has held it in 40 quarters since. The position peaked at $4.01M in Q1 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Susquehanna International Group held 722,119 shares of Akebia Therapeutics worth $1M as of Q1 2026.
  • Susquehanna International Group bought 74,406 Akebia Therapeutics shares in Q1 2026, an estimated $102K.
  • Akebia Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7874 holding.
  • Susquehanna International Group first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 40 quarters since.
  • Susquehanna International Group's Akebia Therapeutics position peaked at $4.01M in Q1 2021.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.